Abstract | BACKGROUND: METHODS: An 8-week, double-blind, placebo-controlled trial was conducted to evaluate the safety and efficacy of oral naltrexone for kleptomania. Twenty-five individuals with DSM-IV kleptomania were randomized to naltrexone (dosing ranging from 50 mg/day to 150 mg/day) or placebo. Twenty-three subjects (92%) completed the study. Subjects were assessed every 2 weeks with the Yale Brown Obsessive Compulsive Scale Modified for Kleptomania (K-YBOCS), the urge and behavior subscales of the K-YBOCS, the Kleptomania Symptom Assessment Scale (K-SAS), the Clinical Global Impressions Scale (CGI), and measures of depression, anxiety, and psychosocial functioning. RESULTS: Subjects assigned to naltrexone had significantly greater reductions in K-YBOCS total scores (p = .001), stealing urges (p = .032), and stealing behavior (p < .001) compared with subjects on placebo. Subjects assigned to naltrexone also had greater improvement in overall kleptomania severity (reflected in the CGI scores) (p < .001). The mean effective dose of naltrexone was 116.7 (+/-44.4) mg/day. CONCLUSIONS:
|
Authors | Jon E Grant, Suck Won Kim, Brian L Odlaug |
Journal | Biological psychiatry
(Biol Psychiatry)
Vol. 65
Issue 7
Pg. 600-6
(Apr 01 2009)
ISSN: 1873-2402 [Electronic] United States |
PMID | 19217077
(Publication Type: Journal Article, Randomized Controlled Trial, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Narcotic Antagonists
- Placebos
- Naltrexone
|
Topics |
- Adolescent
- Adult
- Disruptive, Impulse Control, and Conduct Disorders
(drug therapy)
- Double-Blind Method
- Female
- Humans
- Male
- Middle Aged
- Naltrexone
(adverse effects, therapeutic use)
- Narcotic Antagonists
(adverse effects, therapeutic use)
- Placebos
- Severity of Illness Index
- Theft
(prevention & control)
|